Schisandra for Fatigue
Verdict: Taiwan Regulatory Restriction
Across 3 PubMed studies, the evidence for Schisandra in Fatigue grades Tier C — weak evidence.
C 🟠 C Weak Evidence Taiwan Regulatory Restriction
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.51
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Taiwan Regulatory Restriction
Confidence
85%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.508
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (3)L2 · primary research & systematic reviews
Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial
Finding: Chisan shortened duration of fatigue (1 day) and pain (2 days) in 50% of patients, but significant placebo-vs-active difference reached only for daily walk time and cough, not fatigue itself.
View on PubMed Effect of Schisandra Chinensis Extract Supplementation on Quadriceps Muscle Strength and Fatigue in Adult Women: A Randomized, Double-Blind, Placebo-Controlled Trial
Finding: Treatment group showed increased quadriceps strength (interaction p=0.001) and decreased resting lactate (interaction p=0.038) vs placebo over 12 weeks.
View on PubMed Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions
Finding: ADAPT-232 group showed significantly better attention/speed/accuracy (TN-E scores) vs placebo within 2 hours (p<0.05); single-dose pilot, not fatigue endpoint.
View on PubMed